MX2016007429A - Mezcla de peptidos. - Google Patents
Mezcla de peptidos.Info
- Publication number
- MX2016007429A MX2016007429A MX2016007429A MX2016007429A MX2016007429A MX 2016007429 A MX2016007429 A MX 2016007429A MX 2016007429 A MX2016007429 A MX 2016007429A MX 2016007429 A MX2016007429 A MX 2016007429A MX 2016007429 A MX2016007429 A MX 2016007429A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- point mutation
- peptides
- ras protein
- peptide mixture
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000016914 ras Proteins Human genes 0.000 abstract 3
- 108010014186 ras Proteins Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Abstract
Se describe una mezcla de péptidos adecuada para producir una respuesta inmunitaria. Comprende un primero y un segundo péptido, cada uno que corresponde a un fragmento de la proteína RAS. Cada uno del primero y segundo péptidos comprende una región de al menos 8 aminoácidos que incluye la posición 13 de la proteína RAS. Cada una de las regiones del primero y segundo péptidos tienen independientemente al menos 6 residuos de aminoácido, diferentes en la posición 13, que son idénticos a la región correspondiente de la proteína RAS. Cada uno del primero y segundo péptidos tiene una mutación puntual en el aminoácido que corresponde a la posición 13. La mutación puntual del primer péptido es diferente de la mutación puntual del segundo péptido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 | ||
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007429A true MX2016007429A (es) | 2016-11-11 |
Family
ID=49765823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007429A MX2016007429A (es) | 2013-12-09 | 2014-12-09 | Mezcla de peptidos. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (es) |
| EP (5) | EP3357505A1 (es) |
| JP (2) | JP6781403B2 (es) |
| KR (1) | KR20160097290A (es) |
| CN (1) | CN105980403A (es) |
| AU (2) | AU2014363643B2 (es) |
| BR (1) | BR112016013138A2 (es) |
| CA (1) | CA2933126A1 (es) |
| CL (4) | CL2016001405A1 (es) |
| CY (1) | CY1120578T1 (es) |
| DK (1) | DK3079715T3 (es) |
| ES (1) | ES2682038T3 (es) |
| HR (1) | HRP20181213T1 (es) |
| HU (1) | HUE039840T2 (es) |
| IL (1) | IL246007B2 (es) |
| LT (1) | LT3079715T (es) |
| MX (1) | MX2016007429A (es) |
| PL (1) | PL3079715T3 (es) |
| PT (1) | PT3079715T (es) |
| RS (1) | RS57623B1 (es) |
| RU (1) | RU2016127327A (es) |
| SG (2) | SG11201604644QA (es) |
| SI (1) | SI3079715T1 (es) |
| WO (1) | WO2015086590A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3357505A1 (en) | 2013-12-09 | 2018-08-08 | Targovax Asa | T-cell preparations and mixtures |
| SG11201608712PA (en) | 2014-05-06 | 2016-11-29 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| EP3641807A4 (en) * | 2017-06-22 | 2021-04-21 | The Westmead Institute For Medical Research | ADOPTIVE T-CELL THERAPY 2 |
| TW202015719A (zh) * | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| AU2019324162A1 (en) * | 2018-08-22 | 2021-03-04 | Fred Hutchinson Cancer Center | Immunotherapy targeting KRAS or Her2 antigens |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| US20220378887A1 (en) * | 2019-11-07 | 2022-12-01 | Genoimmune Therapeutics Co., Ltd. | Tumor immunotherapy polypeptide and application thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
| EP4293043A1 (en) * | 2021-02-10 | 2023-12-20 | Shanghai Genbase Biotechnology Co., Ltd. | Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| CN104147597A (zh) | 2002-12-16 | 2014-11-19 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| WO2007133835A2 (en) * | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and mehods related thereto |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| EP3357505A1 (en) | 2013-12-09 | 2018-08-08 | Targovax Asa | T-cell preparations and mixtures |
| SG11201608712PA (en) | 2014-05-06 | 2016-11-29 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
-
2014
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en active Pending
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 US US15/102,681 patent/US9775892B2/en active Active
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en active Application Filing
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en active Pending
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en active Active
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en active Pending
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Application Discontinuation
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-07-30 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en active Active
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007429A (es) | Mezcla de peptidos. | |
| MX2017015927A (es) | Fragmentos mutantes de proteina ras. | |
| NZ746934A (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
| UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
| NZ756395A (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| WO2015179635A3 (en) | Ras inhibitory peptides and uses thereof | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| IN2014DN08325A (es) | ||
| MX2017008406A (es) | Conjugados de aminoacidos y peptidos y sus usos. | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| MX2022011973A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX2017008934A (es) | Método para obtener un aislado de péptidos a partir de una biomasa de microalgas enriquecidas en proteínas. | |
| CO2017012675A2 (es) | Péptidos lipidados resistentes a proteasas | |
| EA201591609A1 (ru) | Варианты альфа-амилазы | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| SG10201805039UA (en) | Protease resistant peptides | |
| NZ760789A (en) | Uti fusion proteins | |
| EP3666897A4 (en) | VERY VERSATILE PROCESS FOR REPRESENTING A CYCLIC PEPTID ON A PROTEIN STRUCTURE | |
| BR112017019202A2 (pt) | ss-frutofuranosidase melhorada | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| WO2016089968A3 (en) | Thermoreversible hydrogels from the arrested phase separation of elastin-like polypeptides | |
| NZ744289A (en) | Composition containing amino acids | |
| WO2012077037A3 (fr) | Peptides modulateurs du complexe saspase-flg2 |